VelaVigo

Executive Summary

VelaVigo is a preclinical-stage biotechnology company pioneering novel therapeutics for neurodegenerative diseases such as Alzheimer's and ALS. Founded in 2020 and headquartered in the United States, the company leverages a proprietary platform that targets specific neuronal pathways implicated in these conditions. With $60 million in total funding, VelaVigo aims to develop disease-modifying treatments that address significant unmet medical needs. The company is privately held and operates with a team of 1-50 employees, focusing on advancing its pipeline through preclinical development toward clinical trials. The neurodegenerative disease landscape is highly competitive, but VelaVigo's targeted approach and platform technology position it as a potential leader in the space. The company's success will depend on its ability to generate compelling preclinical data, secure additional funding for clinical trials, and navigate regulatory pathways. Key upcoming catalysts include the completion of IND-enabling studies and potential partnership announcements that could validate its platform and accelerate development.

Upcoming Catalysts (preview)

• Q3 2026Preclinical data readout for lead candidate in Alzheimer's disease60% success
• Q1 2027IND filing with FDA for lead program50% success
• Q4 2026Series B funding round or strategic partnership70% success